Synairgen PLC (LON:SNG) said it has now commenced dosing patients in its trial of SNG001 (inhaled formulation of interferon-beta-1a) in coronavirus (COVID-19) patients.
The respiratory drug discovery and development company said the first patient has been dosed at the University Hospital Southampton NHS Foundation Trust. Another six trial sites are expected to start dosing in the next few days.
“The team has worked tirelessly and intensively with the relevant authorities and collaborators to get to this stage, and we now look forward to recruiting more patients and completing the trial as soon as possible. A successful outcome from this trial in COVID-19 patients would be a very important step towards a major breakthrough in the fight against this coronavirus pandemic,” Richard Marsden, the chief executive officer of Synairgen said in a statement.